FibroGen to Report First Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day, where management will discuss financial performance and provide a business update. The event will include a live Q&A session following the presentation. Interested participants can access the audio webcast through the company's website, and phone dial-in details will be provided upon registration. A replay of the webcast will be available for a limited time on FibroGen's Events & Presentations webpage.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per luned¨¬ 12 maggio 2025, dopo la chiusura del mercato. La societ¨¤ terr¨¤ una conference call e una presentazione in webcast alle 17:00 ora della costa orientale dello stesso giorno, durante le quali la direzione discuter¨¤ delle performance finanziarie e fornir¨¤ un aggiornamento sul business. L'evento includer¨¤ una sessione di domande e risposte in diretta al termine della presentazione. I partecipanti interessati potranno accedere all'audio webcast tramite il sito web dell'azienda, mentre i dettagli per la chiamata telefonica saranno forniti al momento della registrazione. Una replica del webcast sar¨¤ disponibile per un periodo limitato nella pagina Eventi e Presentazioni di FibroGen.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, despu¨¦s del cierre del mercado. La compa?¨ªa realizar¨¢ una llamada conferencia y una presentaci¨®n por webcast a las 5:00 PM hora del Este ese mismo d¨ªa, donde la direcci¨®n discutir¨¢ el desempe?o financiero y proporcionar¨¢ una actualizaci¨®n del negocio. El evento incluir¨¢ una sesi¨®n de preguntas y respuestas en vivo tras la presentaci¨®n. Los interesados podr¨¢n acceder al audio del webcast a trav¨¦s del sitio web de la empresa, y los detalles para la llamada telef¨®nica se proporcionar¨¢n al registrarse. Una repetici¨®n del webcast estar¨¢ disponible por tiempo limitado en la p¨¢gina de Eventos y Presentaciones de FibroGen.
FibroGen (NASDAQ: FGEN)? 2025? 1?? ?? ?? ??? 2025? 5? 12? ??? ? ?? ?? ???? ????. ??? ?? ? ?? ??? ?? 5?? ???? ?? ???? ??? ????, ???? ?? ??? ???? ?? ??? ????? ?????. ?? ??? ??? ???? ??? ?????. ?? ?? ???? ?? ????? ?? ??? ????? ??? ? ???, ?? ?? ??? ?? ? ?????. ???? ???? FibroGen? ??? ? ?????? ????? ??? ?? ?? ??? ? ????.
FibroGen (NASDAQ : FGEN) a programm¨¦ l'annonce de ses r¨¦sultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025, apr¨¨s la cl?ture des march¨¦s. La soci¨¦t¨¦ organisera une conf¨¦rence t¨¦l¨¦phonique et une pr¨¦sentation en webcast ¨¤ 17h00 heure de l'Est le m¨ºme jour, au cours desquelles la direction discutera des performances financi¨¨res et donnera une mise ¨¤ jour sur les activit¨¦s. L'¨¦v¨¦nement comprendra une session de questions-r¨¦ponses en direct ¨¤ la suite de la pr¨¦sentation. Les participants int¨¦ress¨¦s pourront acc¨¦der au webcast audio via le site web de l'entreprise, et les d¨¦tails pour la connexion t¨¦l¨¦phonique seront fournis lors de l'inscription. Une rediffusion du webcast sera disponible pendant une dur¨¦e limit¨¦e sur la page ?v¨¦nements et Pr¨¦sentations de FibroGen.
FibroGen (NASDAQ: FGEN) hat die Bekanntgabe der Finanzergebnisse f¨¹r das erste Quartal 2025 f¨¹r Montag, den 12. Mai 2025, nach B?rsenschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und eine Webcast-Pr?sentation abhalten, bei der das Management die finanzielle Leistung besprechen und ein Gesch?ftsupdate geben wird. Die Veranstaltung beinhaltet eine Live-Fragerunde nach der Pr?sentation. Interessierte Teilnehmer k?nnen den Audio-Webcast ¨¹ber die Unternehmenswebsite verfolgen, und die Telefon-Einwahldaten werden bei der Anmeldung bereitgestellt. Eine Aufzeichnung des Webcasts wird f¨¹r begrenzte Zeit auf der Seite Veranstaltungen & Pr?sentationen von FibroGen verf¨¹gbar sein.
- None.
- None.
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc.?(NASDAQ: FGEN) will announce first quarter 2025 financial results on?Monday, May 12?after the markets close.?FibroGen?will also conduct a conference call on that day at?5:00 PM Eastern Time?with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen?management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call?. To access the call by phone, please?, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the??page on FibroGen¡¯s website.
About?FibroGen
FibroGen, Inc.?is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (°®Èð׿?, EVRENZO?) is currently approved in?China,?Europe,?Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the?U.S.?FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit?.?
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
FAQ
When will FibroGen (FGEN) report Q1 2025 earnings?
What time is FibroGen's Q1 2025 earnings call?
How can I access FibroGen's Q1 2025 earnings call?
Will there be a replay available for FibroGen's Q1 2025 earnings call?
